Drug intelligence / Profile preview

DF003

Development stage: Preclinical
Lead developer: Drug Farm
Modality: Small Molecules
Administration: Intravitreal

Overview

DF003 is a novel cyclic GMP analogue intended for the treatment of neurodegenerative retinal degenerations. It is formulated into lipid nanocapsules (LNCs) to enable its delivery and sustained release.

Targets

ALPK1 (Alpha-protein kinase 1)

Beyond the preview

Go deeper on DF003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DF003.

Explore the full profile